Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis
- PMID: 37632916
- PMCID: PMC10335144
- DOI: 10.2196/39988
Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis
Abstract
Background: Actinic keratosis (AK) is a common premalignant skin lesion, and topical 5-fluorouracil (5-FU) is commonly used in field-directed therapy. However, 5-FU is associated with frequent local skin reactions.
Objective: This study aimed to qualitatively assess experiences among patients with AK who refuse retreatment with 5-FU.
Methods: Semistructured interviews were conducted with 10 adult participants who had received treatment with 5-FU for AK between January 1, 2017, and January 1, 2020, and refused future treatment with 5-FU. Results were analyzed using qualitative research methods.
Results: Although most participants had low concern upon having received a diagnosis of AK, most felt that treatment is very important. When initiating treatment with 5-FU, most cited recommendation by their health care professionals as the primary motivator and initially had low concern regarding treatment. The side effects associated with treatment were physically and psychosocially burdensome for most participants and led to temporary lifestyle adjustments. After treatment, most did not believe that their health care provider prepared them for treatment or were unsure. While half of the participants felt that 5-FU helped treat AKs, half were either unsure, due to premature discontinuation, or did not think that 5-FU treated their AKs.
Conclusions: 5-FU is one of the most commonly prescribed treatments for AKs, yet most patients experienced both a physical and psychosocial burden with the treatment. Inability to assess efficacy due to premature discontinuation secondary to 5-FU-related reactions is common, and shared decision-making, navigating treatment options, and taking into account patient preferences may be critical to help assure better adherence and outcomes. Although our study was limited by input from participants who refused future treatment with 5-FU, most stated that they would still continue to seek treatment for AKs in the future and would consider other topical treatments, especially if associated with a milder tolerability profile.
Keywords: actinic keratosis; adherence; attitude; attrition; cancer; carcinoma; dermatology; fluorouracil; lesion; malignancy; malignant; neoplasm; oncology; opinion; perception; pharmacological; pharmacotherapy; preference; qualitative; skin; solar keratosis; tolerability; topical 5-fluorouracil; topical treatment.
©Rohan Singh, Sarah McCain, Steven R Feldman. Originally published in JMIR Dermatology (http://derma.jmir.org), 15.02.2023.
Conflict of interest statement
Conflicts of Interest: SRF has received research and speaking or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Baxter, Boeringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Taro, Abbvie, Cosmederm, Anacor, Astellas, Janssen, Lilly, Merck, Merz, Novartis, Regeneron, Sanofi, Novan, Parion, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. He is the founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.RS and SM have no conflicts to disclose.
Similar articles
-
Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review.J Drugs Dermatol. 2022 Jan 1;21(1):60-65. doi: 10.36849/JDD.2022.6632. J Drugs Dermatol. 2022. PMID: 35005863
-
Association Between Local Skin Reactions and Efficacy with 5-Fluorouracil 4% Cream in Actinic Keratosis: A Post-Hoc Analysis of Two Randomised Clinical Trials.Dermatol Ther (Heidelb). 2025 Feb;15(2):307-321. doi: 10.1007/s13555-024-01336-4. Epub 2025 Jan 16. Dermatol Ther (Heidelb). 2025. PMID: 39820963 Free PMC article.
-
A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.Br J Dermatol. 2020 Oct;183(4):738-744. doi: 10.1111/bjd.18884. Epub 2020 Feb 19. Br J Dermatol. 2020. PMID: 31961446 Free PMC article. Clinical Trial.
-
A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis.J Eur Acad Dermatol Venereol. 2015 May;29(5):881-9. doi: 10.1111/jdv.12702. Epub 2014 Sep 25. J Eur Acad Dermatol Venereol. 2015. PMID: 25257941 Clinical Trial.
-
Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.Int J Mol Sci. 2023 Mar 5;24(5):4989. doi: 10.3390/ijms24054989. Int J Mol Sci. 2023. PMID: 36902419 Free PMC article. Review.
Cited by
-
Daylight Photodynamic Therapy for Actinic Keratosis and Field Cancerization: A Narrative Review.Cancers (Basel). 2025 Mar 20;17(6):1050. doi: 10.3390/cancers17061050. Cancers (Basel). 2025. PMID: 40149382 Free PMC article. Review.
-
Effective Treatment of Basal Cell Carcinoma with a Topical Enzymatic Mixture Enriched in Bromelain: Summary of Proof-Of Concept Clinical Studies on the First 22 Tumors.J Clin Med. 2024 Nov 4;13(21):6624. doi: 10.3390/jcm13216624. J Clin Med. 2024. PMID: 39518762 Free PMC article.
-
Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus.Dermatol Pract Concept. 2025 Apr 1;15(2):5787. doi: 10.5826/dpc.1502a5787. Dermatol Pract Concept. 2025. PMID: 40401863 Free PMC article.
References
-
- Hashim PW, Chen T, Rigel D, Bhatia N, Kircik LH. Actinic keratosis: current therapies and insights into new treatments. J Drugs Dermatol. 2019 May 01;18(5):s161–166.S1545961619S0161X - PubMed
-
- Ezzedine K, Painchault C, Brignone M. Systematic literature review and network meta-analysis of the efficacy and acceptability of interventions in actinic keratoses. Acta Derm Venereol. 2021 Jan 04;101(1):adv00358. doi: 10.2340/00015555-3690. https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3690 - DOI - DOI - PMC - PubMed
-
- Rosso JD, Armstrong AW, Berman B, Bhatia N, Cockerell C, Goldenberg G, Kirby J, Lebwohl M, Stein Gold L, Marson JW, Rigel DS. Advances and considerations in the management of actinic keratosis: an expert consensus panel report. J Drugs Dermatol. 2021 Aug 01;20(8):888–893. doi: 10.36849/JDD.6078.S1545961621P0888X - DOI - PubMed
LinkOut - more resources
Full Text Sources